University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

Natalie Galanina, Sonali M. Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao, Ronald Gartenhaus, Jason R. Westin, Kenneth S. Cohen, James A. Knost, Walter M. Stadler, Austin Doyle, Theodore Karrison, Leo I. Gordon, Andrew M. Evens

Research output: Contribution to journalLetterpeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)264-267
Number of pages4
JournalBritish Journal of Haematology
Issue number2
StatePublished - Apr 2018

All Science Journal Classification (ASJC) codes

  • Hematology


  • MEK inhibition
  • novel therapies
  • relapsed/refractory DLBCL
  • selumetinib

Cite this